Loading…
Verastem
VSTM · NASDAQ · Pharmaceutical Preparations
VSTM · NASDAQ · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Needham, Ma.
In the last 90 days, no insider of Verastem reported an open-market purchase and 4 open-market sales worth about $381K. Every figure links to its official SEC, House, Senate or USAspending record.
Revenue
$40.1M
+1775.4% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $136M, at Jun 30, 2026
Net income, last 12 months
−$203M
Operating profit covers interest -108.3x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
4 sales
$381K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$30.9M
+209.1% vs the year before
Net income, fiscal 2025
−$209M
A loss for the year
Shares outstanding
90.6M
As of Aug 3, 2026
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
1 active phase 3 trial and 9 active phase 2 trials led by this company, mostly in low grade ovarian serous adenocarcinoma, low grade serous ovarian cancer, non small cell lung cancer. The ones with the nearest registered primary completion date still ahead:
4 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.